VisionLifesciences

Premium Weekly Newsletter

Dragon Pipeline

Thesis-driven intelligence on China biotech deals, licensing, and pipelines — sourced from Chinese-language primary data.

$69/month

Who reads this

BD executives, licensing professionals, investors, and family offices who need real intelligence on China's biotech ecosystem — not filtered through Western media.

What's inside every issue

4,000-5,000 words of original analysis. 15-20 minute read.

1

Thesis of the Week

Deep analytical piece on one major China biotech theme with investment thesis, competitive landscape, and forward-looking implications.

2

Deal Tracker

5-10 deals of all sizes with company profiles, deal terms from filings, investor analysis, competitive context, and our thesis on why it matters.

3

Regulatory Intelligence

NMPA approvals, CDE review milestones, IND acceptances — sourced directly from Chinese regulatory databases, not Western media.

4

Pipeline Spotlight

Clinical trial milestones from Chinese biotechs: phase transitions, data readouts, partnering potential.

5

Capital Markets Pulse

HKEX Chapter 18A IPOs, STAR Market listings, funding rounds — translated from VCBeat and 36Kr.

6

The Long View

Editorial synthesis connecting the dots: emerging patterns, what's next, what most people aren't seeing.

Our sources

Primary and official sources only. No competitor editorial content. Every claim links to its source.

  • CDE 药审中心 (drug acceptances, review status)
  • NMPA 国家药监局 (approval database, policy)
  • CNINFO 巨潮资讯 (Shenzhen exchange filings)
  • HKEX 港交所 (Chapter 18A biotech filings)
  • SSE 科创板 (STAR Market announcements)
  • VCBeat 动脉网 (healthcare deal flow)
  • 36Kr 36氪医疗 (biotech investment coverage)
  • Bioon 生物谷 (R&D pipeline news)

Why this is different

We mine Chinese-language primary sources daily. Every insight comes from official filings and regulatory databases, translated and analyzed by AI trained on biotech deal-making.

Thesis-driven

Not news. Investment thesis for every deal.

Zero hallucination

Every claim links to an official source.

Primary sources

Official filings, not news aggregation.

Start reading Dragon Pipeline

$69/month. Cancel anytime.